Polymerization shrinkage of methacrylate composites utilizing bisphenol-A glycidal methacylate or urethane dimethacrylate has typically been about 3-3.5% by volume. Though adjustments have been made to filler loading, filler size, filler particle distribution, and improved silanization, the polymerization contraction still creates some significant clinical problems. A new composite utilizing a completely different chemistry has been released, with polymerization shrinkage of less than one percent. This article will review the clinical effects of polymerization contraction of composite resins, the nature and properties of this chemical form of composite, and potential clinical applications.